PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its development program in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION is currently planning to continue the clinical development program by starting a Phase III trial in the second half of 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam.
PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom).
PAION's vision is to become an acknowledged “PAIONeer" in sedation and anesthesia.
PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom).
PAION's vision is to become an acknowledged “PAIONeer" in sedation and anesthesia.
Location: Germany
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
Mentions in press and media 3
| Date | Title | Description |
| 13.07.2011 | Pharmas need new innovation strategy to steer clear of patent cliff, report says | Only 47 percent of executives said their company’s R&D model was capable of meeting their company’s needs. 49 percent rated their company’s overall innovation strategy as just moderately effective at best. And yet, just 54 percent consi... |
| 05.05.2011 | NovaShunt AG raises USD 25 Million in a Series B Financing Co-Led by BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund | NovaShunt AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23.7 million (about $25 million) in a Series B preferred share financing round co-led by BioMedInvest... |
| - | Pharmas need new innovation strategy to steer clear of patent cliff, report says | The patent cliff facing pharmaceutical companies has been staring down the industry for years, but even as companies now watch former blockbuster drugs tumble off its edge, many of those businesses still remain ill equipped to kick-start th... |